All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Norbert Vey, Institut Paoli-Calmettes, Marseilles, FR. We asked: How has the treatment landscape of acute myeloid leukemia evolved in the last five years?
Norbert Vey talks about the new drugs that have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. He discusses the new regimens that are being explored to treat patients, that historically had a dismal prognosis, in hope for better response and overall survival. He also explains the evolving diagnostic techniques (e.g. minimal residual disease status) that are being used to guide AML treatment pathway.
How has the treatment landscape of AML evolved in the last five years?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox